ATE353226T1 - Adjuvanszusammensetzung enthaltend fha oder ein fha-fragment in freier form - Google Patents

Adjuvanszusammensetzung enthaltend fha oder ein fha-fragment in freier form

Info

Publication number
ATE353226T1
ATE353226T1 AT01945376T AT01945376T ATE353226T1 AT E353226 T1 ATE353226 T1 AT E353226T1 AT 01945376 T AT01945376 T AT 01945376T AT 01945376 T AT01945376 T AT 01945376T AT E353226 T1 ATE353226 T1 AT E353226T1
Authority
AT
Austria
Prior art keywords
fha
fragment
free form
composition containing
adjuvant composition
Prior art date
Application number
AT01945376T
Other languages
English (en)
Inventor
Andre Capron
Camille Locht
Franco Menozzi
Odile Poulain-Godefroy
Gilles Riveau
Original Assignee
Pasteur Institut
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut, Inst Nat Sante Rech Med filed Critical Pasteur Institut
Application granted granted Critical
Publication of ATE353226T1 publication Critical patent/ATE353226T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
AT01945376T 2000-06-07 2001-06-07 Adjuvanszusammensetzung enthaltend fha oder ein fha-fragment in freier form ATE353226T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0007302A FR2809960B1 (fr) 2000-06-07 2000-06-07 Composition adjuvante de la reponse immunitaire comprenant la proteine fha ou un fragment de la proteine fha sous forme libre, et composition immunogene ou vaccinale contenant une telle composition adjuvante

Publications (1)

Publication Number Publication Date
ATE353226T1 true ATE353226T1 (de) 2007-02-15

Family

ID=8851056

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01945376T ATE353226T1 (de) 2000-06-07 2001-06-07 Adjuvanszusammensetzung enthaltend fha oder ein fha-fragment in freier form

Country Status (9)

Country Link
US (1) US20050175621A9 (de)
EP (1) EP1292333B1 (de)
JP (1) JP2003535147A (de)
AT (1) ATE353226T1 (de)
AU (2) AU2001267613B2 (de)
CA (1) CA2411578A1 (de)
DE (1) DE60126490D1 (de)
FR (1) FR2809960B1 (de)
WO (1) WO2001093906A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007508368A (ja) * 2003-10-14 2007-04-05 ザ・プロウボウスト・フェロウズ・アンド・スカラーズ・オブ・ザ・カレッジ・オブ・ザ・ホリー・アンド・アンデバイデッド・トリニティ・オブ・クイーン・エリザベス・ニア・ダブリン 免疫介在性疾患の治療及び／又は予防における繊維状血球凝集素
FR2900341B1 (fr) 2006-04-27 2012-09-14 Centre Nat Rech Scient Utilisation de ligands synthetiques multivalents de la nucleoline de surface pour le traitement du cancer
CA2724818C (en) * 2008-05-22 2015-06-16 Centre National De La Recherche Scientifique (Cnrs) New optically pure compounds for improved therapeutic efficiency
JP5865839B2 (ja) * 2010-09-28 2016-02-17 共立製薬株式会社 粘膜アジュバント組成物
CA2813646A1 (en) 2010-10-04 2012-04-12 Robert Zimmer Multivalent synthetic compounds as antibiotic treatment

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0267998A1 (de) * 1986-11-17 1988-05-25 Institut Pasteur Mittel zur Unterstützung gegen Infektion und Vergiftung von Bordetella
EP0484621A3 (en) * 1990-07-11 1992-08-26 American Cyanamid Company Efficacious vaccines against bordetella pertussis comprising a combination of individually purified pertussis antigens
ATE128628T1 (de) * 1990-08-13 1995-10-15 American Cyanamid Co Faser-hemagglutinin von bordetella pertussis als träger für konjugierten impfstoff.
DE19512346C1 (de) * 1995-04-01 1996-06-13 Behringwerke Ag Verfahren zur Reinigung von Filamenthämagglutinin und Pertussis-Toxin

Also Published As

Publication number Publication date
AU2001267613B2 (en) 2006-08-03
US20050175621A9 (en) 2005-08-11
AU6761301A (en) 2001-12-17
EP1292333B1 (de) 2007-02-07
CA2411578A1 (fr) 2001-12-13
FR2809960B1 (fr) 2004-04-23
WO2001093906A1 (fr) 2001-12-13
EP1292333A1 (de) 2003-03-19
FR2809960A1 (fr) 2001-12-14
DE60126490D1 (de) 2007-03-22
US20040047867A1 (en) 2004-03-11
JP2003535147A (ja) 2003-11-25

Similar Documents

Publication Publication Date Title
NO20015073D0 (no) Vaksiner
MY125202A (en) Vaccine
GB0123580D0 (en) Vaccine
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
WO2004030608A3 (en) Nanoemulsion vaccines
DK1104306T3 (da) Præparater af CpG- og saponinadjuvanser og fremgangsmåder til anvendelse deraf
ATE501726T1 (de) Zusammensetzung mit immunogenen mikroteilchen
EP1594536A4 (de) Adjuvante influenza-vakzine
NO20031646L (no) Adjuvanssammensetning omfattende et immunostimulatorisk oligonukleotid og en tokol
NO20063254L (no) Immunstimulerende sammensetning omfattende minst en toll-lignende reseptor 7 eller toll-lignende reseptor 8 agonist og en toll-lignende reseptor 4 agonist
IL150602A (en) Proteosome influenza vaccine, method for preparing such and use thereof
DE60039198D1 (de) Adjuvanszusammensetzungen zur Erhöhung der Immunantwort bezüglich Polynukleotid-basierenden Impfstoffen
ATE286067T1 (de) Hcv hüllproteine partikel : verwendung für therapeutische impfung
CY1117746T1 (el) Αντιγονα αιμοφιλου της γριπης και αντιστοιχα θραυσματα dna
PT1409692E (pt) Novos péptidos do derivados da proteína g do vírus respiratório sincicial (vrs) e sua utilização numa vacina
ATE511855T1 (de) Adjuvansformulierung zur scheimhaut-applikation
AU5577201A (en) Immunogenic pneumococcal protein and vaccine compositions thereof
WO2005007673A3 (en) Immunogenic peptides
DE60136563D1 (de) Salmonella vakzine
ATE353226T1 (de) Adjuvanszusammensetzung enthaltend fha oder ein fha-fragment in freier form
BR0111785A (pt) Composições e métodos para tratamento de candidìase
DE60239753D1 (de) Impfstoff gegen infektiöses lachsanämievirus
MY127452A (en) Vaccines.
DK1159426T3 (da) Kloning og udtryk af Haemophilus somnus transferrin-bindende proteiner
BR0013574A (pt) Antìgeno vacina de moraxella

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties